115 related articles for article (PubMed ID: 37806926)
1. Chronic Glucocorticoid Use and Risk for Advanced Prostate Cancer at Presentation: A SEER-Medicare Cohort Study.
Singh Z; Holt SK; Gore JL; Nyame YA; Wright JL; Schade GR
Clin Genitourin Cancer; 2024 Apr; 22(2):68-73.e2. PubMed ID: 37806926
[TBL] [Abstract][Full Text] [Related]
2. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
3. Aggressive Prostate Cancer at Presentation Following Solid Organ Transplantation.
Singh Z; Holt SK; Gore JL; Nyame YA; Wright JL; Schade GR
Eur Urol Open Sci; 2022 May; 39():79-82. PubMed ID: 35445202
[TBL] [Abstract][Full Text] [Related]
4. Racial Differences in the Surgical Care of Medicare Beneficiaries With Localized Prostate Cancer.
Schmid M; Meyer CP; Reznor G; Choueiri TK; Hanske J; Sammon JD; Abdollah F; Chun FK; Kibel AS; Tucker-Seeley RD; Kantoff PW; Lipsitz SR; Menon M; Nguyen PL; Trinh QD
JAMA Oncol; 2016 Jan; 2(1):85-93. PubMed ID: 26502115
[TBL] [Abstract][Full Text] [Related]
5. Association Between Lead Time and Prostate Cancer Grade: Evidence of Grade Progression from Long-term Follow-up of Large Population-based Cohorts Not Subject to Prostate-specific Antigen Screening.
Assel M; Dahlin A; Ulmert D; Bergh A; Stattin P; Lilja H; Vickers AJ
Eur Urol; 2018 Jun; 73(6):961-967. PubMed ID: 29066048
[TBL] [Abstract][Full Text] [Related]
6. Racial and Ethnic Disparities in Use of Novel Hormonal Therapy Agents in Patients With Prostate Cancer.
Ma TM; Agarwal N; Mahal B; Barragan-Carrillo R; Spratt D; Rettig MB; Valle LF; Steinberg ML; Garraway I; Vapiwala N; Xiang M; Kishan AU
JAMA Netw Open; 2023 Dec; 6(12):e2345906. PubMed ID: 38039002
[TBL] [Abstract][Full Text] [Related]
7. Trends in incidence and 5-year mortality in men with newly diagnosed, metastatic prostate cancer-A population-based analysis of 2 national cohorts.
Helgstrand JT; Røder MA; Klemann N; Toft BG; Lichtensztajn DY; Brooks JD; Brasso K; Vainer B; Iversen P
Cancer; 2018 Jul; 124(14):2931-2938. PubMed ID: 29723398
[TBL] [Abstract][Full Text] [Related]
8. Use of expectant management based on prostate cancer risk and health status: How far are we from a risk-adapted approach?
Spratte BN; Tan HJ; Zambrano IA; Basak RS; Filson CP; Jacobs BL; Hwang S
Urol Oncol; 2023 Jul; 41(7):323.e17-323.e25. PubMed ID: 37149430
[TBL] [Abstract][Full Text] [Related]
9. Baseline Prostate-specific Antigen Level in Midlife and Aggressive Prostate Cancer in Black Men.
Preston MA; Gerke T; Carlsson SV; Signorello L; Sjoberg DD; Markt SC; Kibel AS; Trinh QD; Steinwandel M; Blot W; Vickers AJ; Lilja H; Mucci LA; Wilson KM
Eur Urol; 2019 Mar; 75(3):399-407. PubMed ID: 30237027
[TBL] [Abstract][Full Text] [Related]
10. Prostate-specific antigen-based early detection of prostate cancer--validation of screening without rectal examination.
Schröder FH; Roobol-Bouts M; Vis AN; van der Kwast T; Kranse R
Urology; 2001 Jan; 57(1):83-90. PubMed ID: 11164149
[TBL] [Abstract][Full Text] [Related]
11. Prostate Volume Index Is Able to Differentiate between Prostatic Chronic Inflammation and Prostate Cancer in Patients with Normal Digital Rectal Examination and Prostate-Specific Antigen Values <10 ng/mL: Results of 564 Biopsy Naïve Cases.
Porcaro AB; Tafuri A; Sebben M; Novella G; Processali T; Pirozzi M; Amigoni N; Rizzetto R; Shakir A; Panunzio A; De Michele M; Brunelli M; Cerruto MA; Migliorini F; Siracusano S; Artibani W
Urol Int; 2019; 103(4):415-422. PubMed ID: 31466070
[TBL] [Abstract][Full Text] [Related]
12. The role of the digital rectal examination as diagnostic test for prostate cancer detection in obese patients.
Dell'Atti L
J BUON; 2015; 20(6):1601-5. PubMed ID: 26854458
[TBL] [Abstract][Full Text] [Related]
13. Diagnosis of prostate cancer with needle biopsy: should all cases be biopsied before treatment?
Oranusi CK; Ugezu AI; Nwofor A
Niger J Clin Pract; 2012; 15(1):48-50. PubMed ID: 22437089
[TBL] [Abstract][Full Text] [Related]
14. Prediction of prostate cancer risk: the role of prostate volume and digital rectal examination in the ERSPC risk calculators.
Roobol MJ; van Vugt HA; Loeb S; Zhu X; Bul M; Bangma CH; van Leenders AG; Steyerberg EW; Schröder FH
Eur Urol; 2012 Mar; 61(3):577-83. PubMed ID: 22104592
[TBL] [Abstract][Full Text] [Related]
15. Is there any association between prostate-specific antigen screening frequency and uptake of active surveillance in men with low or very low risk prostate cancer?
Beckmann K; Kinsella N; Olsson H; Wallerstedt Lantz A; Nordstrom T; Aly M; Adolfsson J; Eklund M; Van Hemelrijck M
BMC Urol; 2019 Aug; 19(1):73. PubMed ID: 31383015
[TBL] [Abstract][Full Text] [Related]
16. The role of cytoreductive radical prostatectomy and lymph node dissection in bone-metastatic prostate cancer: A population-based study.
Zhai T; Ma J; Liu Y; Li H; Peng Y; Guo W; Jia J; Wu X; Jiang H; Tian J; Wang D
Cancer Med; 2023 Aug; 12(16):16697-16706. PubMed ID: 37366247
[TBL] [Abstract][Full Text] [Related]
17. Changing Incidence of Metastatic Prostate Cancer by Race and Age, 1988-2015.
Dall'Era MA; deVere-White R; Rodriguez D; Cress R
Eur Urol Focus; 2019 Nov; 5(6):1014-1021. PubMed ID: 29735368
[TBL] [Abstract][Full Text] [Related]
18. BPH: a tell-tale sign of prostate cancer? Results from the Prostate Cancer and Environment Study (PROtEuS).
Boehm K; Valdivieso R; Meskawi M; Larcher A; Sun M; Sosa J; Blanc-Lapierre A; Weiss D; Graefen M; Saad F; Parent MÉ; Karakiewicz PI
World J Urol; 2015 Dec; 33(12):2063-9. PubMed ID: 25824539
[TBL] [Abstract][Full Text] [Related]
19. Baseline PSMA-PET/CT as a predictor of PSA persistence following radical prostatectomy in high-risk nonmetastatic prostate cancer patients receiving neoadjuvant therapy.
Du X; Dong Y; Liu J; Su Y; Zhu Y; Pan J; Dong B; Chen R; Liu J; Tong Z; Pienta KJ; Rowe SP; Dong L; Xue W
Prostate; 2023 Aug; 83(11):1112-1120. PubMed ID: 37165552
[TBL] [Abstract][Full Text] [Related]
20. Family history of prostate and breast cancer and the risk of prostate cancer in the PSA era.
Chen YC; Page JH; Chen R; Giovannucci E
Prostate; 2008 Oct; 68(14):1582-91. PubMed ID: 18646000
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]